Cyclosporin A in a pregnant patient affected with systemic lupus erythematosus.
Few data regarding the use of cyclosporin A (CyA) in pregnancy are available and those available refer mainly to transplant recipients and not to patients with connective tissue diseases. We report the case of a patient with systemic lupus erythematosus (SLE), taking CyA before, during and after her pregnancy at a dose of 4 mg/kg per day. CyA was effective in controlling SLE activity and no side effects were observed in mother or baby. The lack of teratogenicity in this case was in keeping with previous reports in experimental systems, animals and human transplant recipients. If our observation is confirmed by further studies, CyA might become useful in the treatment of pregnant patients with SLE.
Doria
A
A
Division of Rheumatology, Institute of Internal Medicine, Padova, Italy.
Di Lenardo
L
L
Vario
S
S
Calligaro
A
A
Vaccaro
E
E
Gambari
P F
PF
D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D011247:Pregnancy / Q000187:drug effects; D011248:Pregnancy Complications / Q000188:drug therapy*
D016572:Cyclosporine